Industrial conglomerate 3M Company is partnering with the Massachusetts Institute of Technology to develop a cheaper, quicker COVID-19 test.
Right now, test results can take anywhere from a few hours to a week. Quest Diagnostics, for instance, said the average turnaround time at its labs is currently seven days.
3M's new test would function more like a pregnancy strip, a rapid paper-based test that could be mass-produced and quickly distributed at the point of care.
"In terms of patient experience, what we're looking to do is create that low-cost, highly-accurate, simple-to-use test that would be accessible to a lot of people," Dr. John Banovetz, chief technology officer for 3M, told Cheddar.
The antigen-based test, which looks at proteins on the virus, would offer a "preliminary view" of a patient's coronavirus status — though ideally, patients would follow up with a doctor, he added.
"Our goal would be a point-of-care test, so maybe it's taken in a doctor's office. Maybe you pick it up at the pharmacy," Banovetz said.
The goal is to start producing tests by the end of summer or early fall. Once manufacturing is rolling, 3M could produce millions of tests per day, according to the company.
As cases surge across the country and many anticipate a second wave in states where the infection rate has dropped off, calls for more testing are growing.
More than 41 million tests have been reported to the CDC, with a 9 percent positivity rate, but the U.S. continues to lag behind other countries by some measures.
In the meantime, the Trump administration is relying on the private sector to meet the demand for tests, putting pressure on companies such as 3M to come up with a solution.
"We're going as quick as we can right now," he said. "Our focus is trying to get that accuracy up and in a way that we know that we can mass-produce it. That's really where 3M can help contribute to this, our ability to be able to commercialize and bring to market new ideas and innovations."
2021 was an exciting year for space innovations, but 2022 could hold even more in store. Cheddar took a deep dive into the space mission on tap for the year ahead.
The United States purchased over 600,000 doses of a monoclonal antibody treatment from Glaxosmithkline and Vir Biotechnology, bringing the total worldwide doses purchased to 1.7 million. This comes as the country attempts to ramp up treatment options as cases of the omicron variant continue to surge. Dr. Asha Shah, Director of Infectious Diseases at Stamford Health joined Cheddar's Opening Bell to discuss.
As the pandemic slammed the brakes on the nation's economy in 2020, America's greenhouse gas emissions reached their lowest levels in at least three decades. However, as the world, and the economy re-opened, 2021 told a much different story as emissions surged. Biden's flagship 'Build Back Better' act involves billions in spending on electric cars and renewables, in an effort to cut U.S. emissions, experts are still skeptical that the nation will meet the current 2030 target. Andrew Dessler, professor of atmospheric sciences at Texas A&M University, joins Cheddar News.
Amid the omicron surge, a new debate has emerged about whether or not throat swabs are more effective than nasal swabs for COVID testing. Dr. William Schaffner, MD, professor of infectious diseases, Vanderbilt Medical Center, sat down with Cheddar's News Wrap to weigh in on the dispute. "Should there be a change? You've got to do the studies, show that in the field [a throat swab] works as well or better than the nasal specimen," he said. "Let's not do it off our hips, as we say."
Virginia Governor Ralph Northam is declaring a state of emergency after Monday's winter storm left hundreds of drivers stranded on the interstate for more than 24 hours.
The snow also knocked out power for many residents, with more than 100,000 outages remaining days later.
Michael Wehner, a climate scientist at Lawrence Berkeley national laboratory, discusses recent weather disasters.
As the need for COVID-19 testing increases, so does the price of the tests themselves. An agreement with The White House and several major companies to sell the tests at a lower cost has now expired, sending prices up as retailers struggle to keep kits on shelves. Dr. Thomas McGinn, executive VP of physician enterprise at Common Spirit Health, joins Cheddar News to discuss.
A new report shows 2021 saw a surge in U.S. greenhouse gas emissions, indicating that the country remains far off track from meeting President Biden's climate change targets. Biden previously pledged to cut the nation's emissions in half by 2030, and now experts warn that immediate action must be taken in order to get the nation back on track. Zeke Hausfather, director of climate and energy at The Breakthrough Institute on U.S. Emissions and Global Temperatures, joins Cheddar News to discuss.
Electric vehicles are quickly becoming an accessible way for consumers to slash emissions as legacy automakers begin to electrify their fleets and world leaders including President Joe Biden push for broad EV adoption. But consumers have concerns about EV range, the availability of charging stations, and more. What if it were both helpful to consumers — and feasible from a climate change standpoint — to keep hybrid models that run on gas on the market? Gill Pratt, CEO of the Toyota Research Institute & Toyota Motor Corporation's Chief Scientist joins Cheddar Climate to discuss his team's research about 'carbon return on investment,' how Toyota is electrifying its fleet, and more.
According to a recent analysis compiled by The Washington Post, more than four in 10 Americans lived in areas hit by climate-related disasters in 2021. Jonathan Porter, Chief Meteorologist at AccuWeather, joined Cheddar Climate to discuss what this means and what can be done to prevent severe weather events from becoming even worse.
It's a painfully cold week across a large portion of the U.S. with more than 185 million Americans experiencing below-freezing temperatures on Monday and 10 million of them dealing with dangerous sub-zero temps.
